cjc-1295 ipamorelin weight loss evidence safety The peptide problem: Hype is outrunning the CJC-1295/Ipamorelin Dosage: Dosing & Cycle

Now that youre familiar with when and how to use AOD 9604, lets go over some of its safety considerations

Figure 2: Changes in the histolopathological scores amongst the four experimental treatment groups

Contraindications and Precautions Do NOT use AOD-9604 if you: Are pregnant, trying to conceive, or breastfeeding (no safety data in pregnancy/lactation) Have active cancer or history of malignancy (peptide effects on existing cancer unknown) Are under 18 years of age (pediatric safety not established) Have known hypersensitivity to peptides or benzyl alcohol (in bacteriostatic water) Have severe kidney or liver disease without physician clearance Use with caution and enhanced monitoring if you have: Diabetes or glucose metabolism disorders (monitor blood sugar closely despite no expected impact) Cardiovascular disease (comprehensive cardiac evaluation recommended) Thyroid disorders (monitor thyroid function during therapy) History of migraines (may increase headache frequency in susceptible individuals) Drug Interactions Limited formal drug interaction studies exist for AOD-9604

PLoS ONE 8 , 63887 (2013)

No, AOD-9604 does not suppress appetite or reduce hunger